<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004276</url>
  </required_header>
  <id_info>
    <org_study_id>199/11682</org_study_id>
    <secondary_id>RU-0300395</secondary_id>
    <nct_id>NCT00004276</nct_id>
  </id_info>
  <brief_title>Phase II Placebo Controlled Study of Thalidomide in Patients With Mycobacterial and HIV Infections</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rockefeller University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Office of Rare Diseases (ORD)</source>
  <brief_summary>
    <textblock>
      OBJECTIVES: I. Evaluate whether thalidomide modulates toxic host inflammatory responses in
      patients receiving antitubercular therapy.

      II. Evaluate whether thalidomide modifies tumor necrosis factor-mediated toxic symptoms of
      HIV and mycobacterial infections, and limits progression of HIV immunodeficiency.

      III. Evaluate whether thalidomide stimulates immunity in patients with HIV and/or
      mycobacterial infections.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE: This is a randomized, double blind study. Patients are stratified by type
      of infection.

      Patients are randomly assigned to oral thalidomide or placebo. Therapy is administered daily
      for up to 8 weeks, beginning the night before antitubercular treatment is initiated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 1990</start_date>
  <completion_date>June 1999</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>50</enrollment>
  <condition>HIV Infections</condition>
  <condition>Mycobacterium Infections</condition>
  <condition>Tuberculosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thalidomide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:

        --Disease Characteristics--

        Human immunodeficiency virus (HIV) or mycobacterial infection that requires at least 10
        days of inpatient antitubercular treatment

        Mycobacterial infection confirmed by positive acid-fast bacilli smear or culture for
        Mycobacterium tuberculosis

        At least 1 of the following signs and symptoms required:

          -  Temperature over 38 degrees C on at least 2 occasions within 1 week prior to treatment

          -  Weight loss greater than 5 kg

          -  Pulmonary involvement in at least 1 lobe on x-ray

        Night sweats on at least 2 occasions within 1 week prior to treatment

        --Prior/Concurrent Therapy--

        Concurrent rifampicin, isoniazid, pyrazinamide, and ethambutol for tuberculosis allowed

        --Patient Characteristics--

          -  No neuropathy and not at risk for neuropathy

          -  Not pregnant

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for 4 weeks after study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilla Kaplan</last_name>
    <role>Study Chair</role>
    <affiliation>Rockefeller University</affiliation>
  </overall_official>
  <reference>
    <citation>Haslett P, Tramontana J, Burroughs M, Hempstead M, Kaplan G. Adverse reactions to thalidomide in patients infected with human immunodeficiency virus. Clin Infect Dis. 1997 Jun;24(6):1223-7.</citation>
    <PMID>9195087</PMID>
  </reference>
  <reference>
    <citation>Tramontana JM, Utaipat U, Molloy A, Akarasewi P, Burroughs M, Makonkawkeyoon S, Johnson B, Klausner JD, Rom W, Kaplan G. Thalidomide treatment reduces tumor necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis. Mol Med. 1995 May;1(4):384-97.</citation>
    <PMID>8521296</PMID>
  </reference>
  <reference>
    <citation>Haslett P, Hempstead M, Seidman C, Diakun J, Vasquez D, Freedman VH, Kaplan G. The metabolic and immunologic effects of short-term thalidomide treatment of patients infected with the human immunodeficiency virus. AIDS Res Hum Retroviruses. 1997 Aug 10;13(12):1047-54.</citation>
    <PMID>9264292</PMID>
  </reference>
  <reference>
    <citation>Bekker LG, Haslett P, Maartens G, Steyn L, Kaplan G. Thalidomide-induced antigen-specific immune stimulation in patients with human immunodeficiency virus type 1 and tuberculosis. J Infect Dis. 2000 Mar;181(3):954-65.</citation>
    <PMID>10720518</PMID>
  </reference>
  <reference>
    <citation>Klausner JD, Makonkawkeyoon S, Akarasewi P, Nakata K, Kasinrerk W, Corral L, Dewar RL, Lane HC, Freedman VH, Kaplan G. The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M. tuberculosis infection. J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Mar 1;11(3):247-57.</citation>
    <PMID>8603261</PMID>
  </reference>
  <verification_date>December 2001</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 1999</study_first_submitted>
  <study_first_submitted_qc>October 18, 1999</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 1999</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>bacterial infection</keyword>
  <keyword>human immunodeficiency virus infection</keyword>
  <keyword>immunologic disorders and infectious disorders</keyword>
  <keyword>mycobacterium infection</keyword>
  <keyword>mycobacterium tuberculosis infection</keyword>
  <keyword>rare disease</keyword>
  <keyword>viral infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Mycobacterium Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

